Cytomegalovirus envelope glycoprotein

Cytomegalovirus envelope glycoproteins are a diverse group of viral membrane proteins located on the envelope of human cytomegalovirus (HCMV), an important human pathogen in immunocompromised hosts and a major cause of congenital infection[1][3][4][6]. The most studied are glycoprotein B (gB), the essential fusogen that enables membrane fusion; glycoprotein H (gH) and glycoprotein L (gL), which, together with either glycoprotein O (gO) or the UL128-131A complex, form trimeric and pentameric complexes that mediate cell entry and determine cell tropism. Other notable proteins include gM/gN, involved in initial host interactions. These glycoproteins are primary targets for neutralizing antibodies, vaccine candidates, and monoclonal antibody therapies but are complicated by sequence variability and immune evasion strategies such as glycan shielding. Clinical interventions seek to block their function, preventing host infection and virus spread[3][4][6][7][9]. Note: For structured data applications, refer to individual glycoproteins (e.g., "Cytomegalovirus envelope glycoprotein B" or "Cytomegalovirus envelope glycoprotein H") since "envelope glycoproteins" is not a discrete molecular entity but a functional grouping.

Other names

Human cytomegalovirus envelope glycoproteinsHCMV envelope glycoproteinsViral envelope proteins (general)Individual names include: glycoprotein B (gB), glycoprotein H (gH), glycoprotein L (gL), glycoprotein O (gO), glycoprotein M (gM), glycoprotein N (gN), pentameric complex, trimeric complex

Neutralization of viral entry by blocking host cell binding or membrane fusion - Vaccine-induced immune response/antibody production against envelope glycoproteins - Inhibition of glycoprotein function (antagonists, e.g., US28 antagonists)